KR20170057384A - 피친데 바이러스 역유전학 시스템 및 이용 방법 - Google Patents

피친데 바이러스 역유전학 시스템 및 이용 방법 Download PDF

Info

Publication number
KR20170057384A
KR20170057384A KR1020177010589A KR20177010589A KR20170057384A KR 20170057384 A KR20170057384 A KR 20170057384A KR 1020177010589 A KR1020177010589 A KR 1020177010589A KR 20177010589 A KR20177010589 A KR 20177010589A KR 20170057384 A KR20170057384 A KR 20170057384A
Authority
KR
South Korea
Prior art keywords
protein
leu
virus
genome
coding region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020177010589A
Other languages
English (en)
Korean (ko)
Inventor
힌 리
유잉 리앙
Original Assignee
리젠츠 오브 더 유니버시티 오브 미네소타
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리젠츠 오브 더 유니버시티 오브 미네소타 filed Critical 리젠츠 오브 더 유니버시티 오브 미네소타
Publication of KR20170057384A publication Critical patent/KR20170057384A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/10011Arenaviridae
    • C12N2760/10041Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020177010589A 2014-09-22 2015-09-22 피친데 바이러스 역유전학 시스템 및 이용 방법 Withdrawn KR20170057384A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053443P 2014-09-22 2014-09-22
US62/053,443 2014-09-22
PCT/US2015/051337 WO2016048949A1 (en) 2014-09-22 2015-09-22 Pichinde virus reverse genetics system and methods of use

Publications (1)

Publication Number Publication Date
KR20170057384A true KR20170057384A (ko) 2017-05-24

Family

ID=54238628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177010589A Withdrawn KR20170057384A (ko) 2014-09-22 2015-09-22 피친데 바이러스 역유전학 시스템 및 이용 방법

Country Status (12)

Country Link
US (2) US10533159B2 (https=)
EP (1) EP3198008B1 (https=)
JP (1) JP6875274B6 (https=)
KR (1) KR20170057384A (https=)
CN (1) CN107109371A (https=)
AU (1) AU2015321557B2 (https=)
BR (1) BR112017005744B1 (https=)
CA (1) CA2961913A1 (https=)
ES (1) ES2746150T3 (https=)
MX (1) MX391006B (https=)
PL (1) PL3198008T3 (https=)
WO (1) WO2016048949A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107109371A (zh) 2014-09-22 2017-08-29 明尼苏达大学评议会 皮钦德病毒反向遗传学系统及其使用方法
SI3218504T1 (sl) * 2014-11-13 2020-11-30 Universite De Geneve Tri-segmentirani arenavirusi kot vakcinski vektorji
AU2016274655B2 (en) 2015-06-10 2021-06-17 NeoTrail Therapeutics, Inc. HPV vaccines
CA3003557A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
DK3373959T3 (da) 2015-11-12 2022-09-19 Hookipa Biotech Gmbh Arenaviruspartikler som cancervacciner
IL262963B2 (en) * 2016-05-18 2025-01-01 Hookipa Biotech Gmbh Trisegmented PICHINDE viruses as vaccine vectors
US20230310574A1 (en) * 2020-08-06 2023-10-05 Regents Of The University Of Minnesota Multivalent vaccines against turkey arthritis reovirus
WO2022269362A2 (en) 2021-06-21 2022-12-29 Vaxxinova International B.V. Veterinary viral vector
WO2024155646A1 (en) * 2023-01-17 2024-07-25 Regents Of The University Of Minnesota Multivalent vaccines against tuberculosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2170622B1 (es) 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
ES2424214T3 (es) 2007-08-27 2013-09-30 Siga Technologies, Inc. Medicamentos antivirales para el tratamiento de una infección por Arenavirus
AP3126A (en) 2007-12-21 2015-02-28 Government Of The Us Secretary Recombinant rift valley fever (RVF) viruses and methods of use
SI2604695T1 (sl) * 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
EP2478103A4 (en) 2009-09-16 2014-02-19 Univ Tulane LASSAVIRUS-like PARTICLES AND METHOD FOR THE PRODUCTION THEREOF
GB201007790D0 (en) 2010-05-10 2010-06-23 Isis Innovation Compositions
JP2013531496A (ja) 2010-06-06 2013-08-08 モウント シナイ スクール オフ メディシネ 組換えrnaウイルス及びその使用
CN107109371A (zh) 2014-09-22 2017-08-29 明尼苏达大学评议会 皮钦德病毒反向遗传学系统及其使用方法

Also Published As

Publication number Publication date
PL3198008T3 (pl) 2020-03-31
EP3198008B1 (en) 2019-05-29
ES2746150T3 (es) 2020-03-04
WO2016048949A1 (en) 2016-03-31
BR112017005744B1 (pt) 2023-11-28
US11993789B2 (en) 2024-05-28
BR112017005744A2 (pt) 2017-12-12
CN107109371A (zh) 2017-08-29
US20200165578A1 (en) 2020-05-28
AU2015321557B2 (en) 2020-05-14
US20170292119A1 (en) 2017-10-12
AU2015321557A1 (en) 2017-04-06
MX391006B (es) 2025-03-21
JP6875274B2 (ja) 2021-05-19
EP3198008A1 (en) 2017-08-02
CA2961913A1 (en) 2016-03-31
JP2017529084A (ja) 2017-10-05
US10533159B2 (en) 2020-01-14
MX2017003694A (es) 2017-10-12
JP6875274B6 (ja) 2021-06-30

Similar Documents

Publication Publication Date Title
US11993789B2 (en) Pichinde virus reverse genetics systems and methods of use
Xiao et al. A defective viral genome strategy elicits broad protective immunity against respiratory viruses
JP2017529084A5 (https=)
Kraatz et al. Deletion mutants of Schmallenberg virus are avirulent and protect from virus challenge
Sheahan et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus
Sun et al. Methyltransferase-defective avian metapneumovirus vaccines provide complete protection against challenge with the homologous Colorado strain and the heterologous Minnesota strain
US20260014243A1 (en) Crimean-congo hemorrhagic fever virus replicon particles and use thereof
CN104017775A (zh) 能够感染犬科动物的流感病毒及其用途
Ghorbani et al. Viral subpopulation screening guides in designing a high interferon-inducing live attenuated influenza vaccine by targeting rare mutations in NS1 and PB2 proteins
CN107208071A (zh) 用于流感病毒的减弱活疫苗
EP4196158A1 (en) Salmonella vaccine for the treatment of coronavirus
Bergthaler et al. Envelope exchange for the generation of live-attenuated arenavirus vaccines
JP2023532735A (ja) 組み換えエンテロウイルスおよびその使用
Ngunjiri et al. In vivo assessment of NS1-truncated influenza virus with a novel SLSYSINWRH motif as a self-adjuvanting live attenuated vaccine
Wang et al. Genome‐Wide Codon Reprogramming Enables a Multifactorially Attenuated Influenza Vaccine with Broad Cross‐Protection
Groenke Molecular mechanism of virus attenuation by codon pair deoptimization
US20230310574A1 (en) Multivalent vaccines against turkey arthritis reovirus
Wang et al. A novel self-amplified RNA vaccine co-expressing NA and HA1 delivered by Salmonella confers potent protection against H9N2 influenza in chickens
JP2023525623A (ja) 核酸構築物、組み換えインフルエンザウイルス、組み換えインフルエンザウイルスを調製するための方法、組成物、および使用
Vyas CHARACTERIZING PHENOTYPIC DIFFERENCES BETWEEN THE HA PROTEIN FROM TWO CLADES OF H3N2 INFLUENZA A VIRUSES FROM THE 2016-17 AND 2017-18 US SEASONAL OUTBREAKS
EP3939991A2 (en) Novel recombinant influenza virus having immune and therapeutic responses to heterologous influenza virus, and genetic vector and therapeutic vaccine comprising same
WO2022269362A2 (en) Veterinary viral vector
CN118574926A (zh) 合理设计的单轮感染性病毒及其使用方法
Haas et al. Replication competent, 10-segmented influenza viruses as antiviral therapeutics
Tully Towards the development of a universal influenza vaccine: investigating viral-vectored vaccine-induced heterosubtypic immune responses to influenza A

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination